Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04616807
Other study ID # LUP/MEX/2018/001
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date December 17, 2020
Est. completion date January 24, 2026

Study information

Verified date May 2024
Source Lupin Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a non-interventional, prospective, observational, multicentre study to evaluate the long-term safety and effectiveness of Namuscla in adult patients with NDM.


Description:

This is a non-interventional, prospective, observational, multicentre study to evaluate the long-term safety and effectiveness of Namuscla in adult patients with NDM. Namuscla should be prescribed as per the approved Summary of Product Characteristics (SmPC). Adult patients with non-dystrophic myotonic disorders who have been prescribed Namuscla by the treating physician, and who meet the eligibility criteria will be enrolled in this study. This includes: - Patients newly initiated on Namuscla for the treatment of NDM (newly exposed) - Patients already on Namuscla/ mexiletine at enrolment - For patients receiving mexiletine other than Namuscla, only those who switch to Namuscla will be included in the study. Patients already being treated with Namuscla/ mexiletine at the time of enrolment will be considered for enrolment provided they meet the eligibility criteria. The study will be initiated at specialized centres for the treatment of myotonic disorders ("reference centres") in the United Kingdom (UK), France, and Germany, depending on availability of Namuscla in the specific country. Depending on the enrolment and marketing status (availability) of Namuscla in other countries in the EU, inclusion of additional sites in other countries will be considered. The study population will comprise patients who are diagnosed with non-dystrophic myotonic disorders and considered suitable candidates for the treatment by Namuscla by the investigators according to the approved SmPC. Patients will be enrolled over an approximate 2-year enrolment period and will be followed-up on-treatment for up to 3 years. Each enrolled patient will be observed for 3 years or until discontinuation (if discontinued early). For all enrolled patients, the baseline would be the latest data available at the enrolment visit. For the patients already on Namuscla, cumulative data (data related previous exposure as well as current data) will be collected for adverse events (AEs) on Namuscla treatment. No drug will be supplied for this study; patients will receive medicines through local standard practices. All evaluations and investigations during the study will be performed according to the routine clinical practices and discretion of the treating physician.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 53
Est. completion date January 24, 2026
Est. primary completion date December 19, 2025
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adult, male or female patients with non-dystrophic myotonic disorders planned to be started on Namuscla according to the approved SmPC 2. Patients already receiving Namuscla/mexiletine for the treatment of NDM; (for patients on mexiletine other than Namuscla, only those who switch to Namuscla will be enrolled). 3. Patients who understand and are willing to provide informed consent. Exclusion Criteria: 1. Patients who are enrolled or participating in any other clinical trial for an investigational product. - 2. Hypersensitivity to mexiletine, or to any of the excipients of Namuscla, or hypersensitivity to any local anaesthetic 3. Ventricular tachyarrhythmia 4. Atrial tachyarrhythmia, fibrillation or flutter 5. Complete heart block (ie, third-degree atrioventricular block) or any heart block susceptible to evolve to complete heart block (first-degree atrioventricular block with markedly prolonged PR interval (= 240 ms) and/or wide QRS complex (= 120 ms), second-degree atrioventricular block, bundle branch block, bifascicular and trifascicular block), 6. Myocardial infarction (acute or past), or abnormal Q-waves 7. Symptomatic coronary artery disease 8. Heart failure with reduced ejection fraction <50% 9. Sinus node dysfunction (including sinus rate < 50 bpm) 10. Patients receiving drugs that can induce torsades de pointes 11. Patients receiving medicinal products with narrow therapeutic index (ie, theophylline, tizanidine, digoxin, lithium, phenytoin or warfarin) 12. Patients who are pregnant or lactating.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mexiletine
Observational Study

Locations

Country Name City State
France CHRU Lille Lille
France Hôpital Universitaire de La Pitié Salpêtrière Paris Cedex
Germany St. Josef-Hospital Klinikum der Ruhr Universitaet Bochum Bochum North-Rhine Westphalia
Germany Universitätsklinikum Ulm, Klinik für Neurologie Ulm
United Kingdom Institute of Neurology London England
United Kingdom Nottingham University Hospitals NHS Trust Nottingham England

Sponsors (1)

Lead Sponsor Collaborator
Lupin Ltd.

Countries where clinical trial is conducted

France,  Germany,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Outcome 1 Proportion of patients with treatment-emergent AEs Proportion of patients with treatment-emergent AEs ([TEAEs], including SAEs) from study enrolment to 6, 12, 24 and 36 months on Namuscla Approximately 3 years
Primary Primary Outcome 2 Proportion of patients requiring dose reduction or treatment discontinuation Proportion of patients requiring dose reduction or treatment discontinuation due to AEs (including SAEs). Approximately 3 years
Secondary Secondary Outcome Proportion of patients with AEs /SAEs/ Adverse Event of Special Interest (AESI) Proportion of patients with AEs /SAEs/ Adverse Event of Special Interest (AESI) from study enrolment to 6, 12, 24, and 36 months Approximately 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04624750 - Open Label Study in Adolescents and Children With Myotonic Disorders Phase 3
Recruiting NCT00082108 - Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Recruiting NCT05890833 - The Risk of Falls Index for Patients With Neuromuscular Disorders
Completed NCT05027269 - Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients Phase 1/Phase 2
Completed NCT00233519 - Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) Phase 1/Phase 2
Completed NCT00167609 - Efficacy and Safety of DHEA for Myotonic Dystrophy Phase 2/Phase 3
Recruiting NCT06411288 - Global Study of Del-desiran for the Treatment of DM1 Phase 3
Recruiting NCT04003363 - The United Kingdom National Registry for Myotonic Dystrophy
Completed NCT01136330 - DM1 Heart Registry - DM1 Respiratory Registry N/A
Completed NCT02375087 - Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ?
Completed NCT01406873 - Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 Phase 2
Completed NCT03959189 - Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 Phase 1
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Recruiting NCT00127582 - RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy Phase 3
Recruiting NCT02398786 - Myotonic Dystrophy Family Registry
Recruiting NCT05019625 - Biomarker Development for Muscular Dystrophies
Recruiting NCT05020002 - Extracellular RNA Biomarkers of Myotonic Dystrophy
Active, not recruiting NCT05479981 - Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients Phase 2
Terminated NCT02315339 - European Home Mechanical Ventilation Registry
Not yet recruiting NCT06147414 - Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders